{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:13:18Z","timestamp":1793679198651,"version":"4.5.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Novel plasma assays enabled accurate blood-based biomarkers for neurodegenerative diseases with minimally invasive options for clinical use. Large-scale studies encompassing multiple neurodegenerative diseases using novel multiplex platforms are essential to uncover disease-specific biomarkers and pathways. We generated and analyzed plasma biomarker data using the NULISAseq\u2122 CNS Panel from 3,232 participants with Alzheimer disease (AD), Dementia with Lewy bodies (DLB), Frontotemporal dementia (FTD), Parkinson disease (PD) and cognitively unimpaired individuals, from the Charles F. and Joanne Knight Alzheimer Disease Research Center. We identified proteins associated with disease status and AD-related phenotypes (Clinical Dementia Rating\u00ae, CSF A\u03b242\/A\u03b240, Amyloid-PET, and Tau-PET). These proteins were used to identify disease-specific biomarkers and perform pathway analyses. We identified 81 proteins associated with AD, 21 with DLB, four with FTD, and 52 with PD after multiple test correction. Disease comparison showed that PD and DLB had the highest similarity, followed by AD and DLB. Concurrently, each disease also presented disease-specific signatures. Some AD-specific proteins included p-tau217; MSLN and SAA1 were specific to DLB, and FLT1 and PARK7 to PD. We also identified eight proteins associated with Amyloid-PET, eight with Tau-PET, 14 with CSF A\u03b242\/40 ratio, and 72 with CDR, some of which were specific to each phenotype. We used a data-driven approach to identify the p-tau217 cut-off for biomarker positivity. Plasma p-tau217 achieved an AUC of 0.81 (95% CI: 0.79\u20130.83) for AD diagnosis and 0.96 (95% CI: 0.94\u20130.98) for Amyloid positivity. P-tau217 had 93.77% agreement with Amyloid-PET status. Proteins associated with AD were enriched in protein-lipid complex binding pathway, whereas PD associated proteins were enriched in laminin-related pathways. FTD associated proteins were enriched in cytoskeleton proteins. This is the largest plasma NULISA CNS study performed till date and covers the four major neurodegenerative diseases: AD, PD, DLB and FTD. We validated the high classification accuracy of the NULISA plasma p-tau217 and its strong correlation with Amyloid-PET status. We also identified disease-specific proteins that could enhance differential diagnosis. These findings highlight the potential of the NULISA platform as a reliable quantitative tool for research and clinical applications in neurodegenerative diseases.<\/jats:p>","DOI":"10.1186\/s13024-025-00909-x","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T17:54:50Z","timestamp":1763402090000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["High-sensitivity plasma proteomics reveals disease-specific signatures and predictive biomarkers of Alzheimer\u2019s disease phenotypes in a large mixed-dementia cohort"],"prefix":"10.1186","volume":"20","author":[{"given":"Katherine","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jigyasha","family":"Timsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yike","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Pottier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey K.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyujin","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammie L.","family":"S. Benzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus A.","family":"Raji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beau","family":"Ances","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie K.","family":"Wisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne E.","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Holtzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ibanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cruchaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"issue":"4","key":"909_CR1","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.14283\/jpad.2024.21","volume":"11","author":"Z Li","year":"2024","unstructured":"Li Z, Yang N, He L, et al. Global burden of dementia death from 1990 to 2019, with projections to 2050: an analysis of 2019 Global Burden Of Disease Study. J Prev Alzheimers Dis. 2024;11(4):1013\u201321. https:\/\/doi.org\/10.14283\/jpad.2024.21.","journal-title":"J Prev Alzheimers Dis"},{"issue":"5","key":"909_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"VL Feigin","year":"2019","unstructured":"Feigin VL, Nichols E, Alam T, et al. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden Of Disease Study 2016. The Lancet Neurol. 2019;18(5):459\u201380. https:\/\/doi.org\/10.1016\/S1474-4422(18)30499-X.","journal-title":"The Lancet Neurol"},{"key":"909_CR3","doi-asserted-by":"publisher","unstructured":"Alzheimer\u2019s disease facts and figures. Alzheimers Dement J Alzheimers Assoc. 2024. 2024;20(5):3708\u2013821. https:\/\/doi.org\/10.1002\/alz.13809.","DOI":"10.1002\/alz.13809"},{"issue":"2","key":"909_CR4","doi-asserted-by":"publisher","first-page":"e12465","DOI":"10.1002\/trc2.12465","volume":"10","author":"J Cummings","year":"2024","unstructured":"Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer\u2019s disease drug development pipeline: 2024. Alzheimers Dement Transl Res Clin Interv. 2024;10(2):e12465. https:\/\/doi.org\/10.1002\/trc2.12465.","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"issue":"9","key":"909_CR5","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/s41591-023-02505-2","volume":"29","author":"WK Self","year":"2023","unstructured":"Self WK, Holtzman DM. Emerging diagnostics and therapeutics for Alzheimer disease. Nat Med. 2023;29(9):2187\u201399. https:\/\/doi.org\/10.1038\/s41591-023-02505-2.","journal-title":"Nat Med"},{"issue":"1","key":"909_CR6","doi-asserted-by":"publisher","first-page":"e14408","DOI":"10.15252\/emmm.202114408","volume":"14","author":"A Leuzy","year":"2022","unstructured":"Leuzy A, Mattsson-Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O. Blood-based biomarkers for Alzheimer\u2019s disease. EMBO Mol Med. 2022;14(1):e14408. https:\/\/doi.org\/10.15252\/emmm.202114408.","journal-title":"EMBO Mol Med"},{"issue":"6","key":"909_CR7","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1515\/cclm-2023-1434","volume":"62","author":"B Arslan","year":"2024","unstructured":"Arslan B, Zetterberg H, Ashton NJ. Blood-based biomarkers in Alzheimer\u2019s disease - moving towards a new era of diagnostics. Clin Chem Lab Med CCLM. 2024;62(6):1063\u201369. https:\/\/doi.org\/10.1515\/cclm-2023-1434.","journal-title":"Clin Chem Lab Med CCLM"},{"key":"909_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13195-024-01513-9","volume":"16","author":"J Arranz","year":"2024","unstructured":"Arranz J, Zhu N, Rubio-Guerra S, et al. Diagnostic performance of plasma pTau217, pTau181, A\u03b21-42 and A\u03b21-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease. Alzheimers Res Ther. 2024;16:139. https:\/\/doi.org\/10.1186\/s13195-024-01513-9.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"909_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s43587-020-00008-0","volume":"1","author":"SE Schindler","year":"2021","unstructured":"Schindler SE, Bateman RJ. Combining blood-based biomarkers to predict risk for Alzheimer\u2019s disease dementia. Nat Aging. 2021;1(1):26\u201328. https:\/\/doi.org\/10.1038\/s43587-020-00008-0.","journal-title":"Nat Aging"},{"issue":"12","key":"909_CR10","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson O, Edelmayer RM, Boxer AL, et al. The Alzheimer\u2019s association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement J Alzheimers Assoc. 2022;18(12):2669\u201386. https:\/\/doi.org\/10.1002\/alz.12756.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"issue":"1","key":"909_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00401-024-02706-0","volume":"147","author":"J Rutledge","year":"2024","unstructured":"Rutledge J, Lehallier B, Zarifkar P, et al. Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson\u2019s disease. Acta Neuropathol (Berl). 2024;147(1):52. https:\/\/doi.org\/10.1007\/s00401-024-02706-0.","journal-title":"Acta Neuropathol (Berl)"},{"issue":"6","key":"909_CR12","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1038\/s41591-024-02937-4","volume":"30","author":"M Chatterjee","year":"2024","unstructured":"Chatterjee M, \u00d6zdemir S, Fritz C, et al. Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS. Nat Med. 2024;30(6):1771\u201383. https:\/\/doi.org\/10.1038\/s41591-024-02937-4.","journal-title":"Nat Med"},{"issue":"4","key":"909_CR13","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1002\/alz.13653","volume":"20","author":"P Diaz-Galvan","year":"2024","unstructured":"Diaz-Galvan P, Przybelski SA, Algeciras-Schimnich A, et al. Plasma biomarkers of Alzheimer\u2019s disease in the continuum of dementia with Lewy bodies. Alzheimers Dement. 2024;20(4):2485\u201396. https:\/\/doi.org\/10.1002\/alz.13653.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"909_CR14","doi-asserted-by":"publisher","first-page":"7238","DOI":"10.1038\/s41467-023-42834-x","volume":"14","author":"W Feng","year":"2023","unstructured":"Feng W, Beer JC, Hao Q, et al. NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing. Nat Commun. 2023;14(1):7238. https:\/\/doi.org\/10.1038\/s41467-023-42834-x.","journal-title":"Nat Commun"},{"issue":"2","key":"909_CR15","doi-asserted-by":"publisher","first-page":"e14413","DOI":"10.1002\/alz.14413","volume":"21","author":"L Ibanez","year":"2025","unstructured":"Ibanez L, Liu M, Beric A, et al. Benchmarking of a multi-biomarker low-volume panel for Alzheimer\u2019s disease and related dementia research. Alzheimers Dement. 2025;21(2):e14413. https:\/\/doi.org\/10.1002\/alz.14413.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"909_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13024-024-00753-5","volume":"19","author":"X Zeng","year":"2024","unstructured":"Zeng X, Lafferty TK, Sehrawat A, et al. Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer\u2019s disease. Mol Neurodegener. 2024;19(1):68. https:\/\/doi.org\/10.1186\/s13024-024-00753-5.","journal-title":"Mol Neurodegener"},{"key":"909_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.neuroimage.2014.11.058","volume":"107","author":"Y Su","year":"2015","unstructured":"Su Y, Blazey TM, Snyder AZ, et al. Partial volume correction in quantitative amyloid imaging. NeuroImage. 2015;107:55\u201364. https:\/\/doi.org\/10.1016\/j.neuroimage.2014.11.058.","journal-title":"NeuroImage"},{"issue":"12","key":"909_CR18","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.2967\/jnumed.119.228510","volume":"60","author":"M Tahmi","year":"2019","unstructured":"Tahmi M, Bou-Zeid W, Razlighi QR. A fully automatic technique for precise localization and quantification of amyloid-\u03b2 PET scans. J Nucl Med. 2019;60(12):1771\u201379. https:\/\/doi.org\/10.2967\/jnumed.119.228510.","journal-title":"J Nucl Med"},{"issue":"10","key":"909_CR19","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","volume":"49","author":"HG Pemberton","year":"2022","unstructured":"Pemberton HG, Collij LE, Heeman F, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imag. 2022;49(10):3508\u201328. https:\/\/doi.org\/10.1007\/s00259-022-05784-y.","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"909_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.neuroimage.2017.07.050","volume":"161","author":"S Mishra","year":"2017","unstructured":"Mishra S, Gordon BA, Su Y, et al. AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: defining a summary measure. NeuroImage. 2017;161:171\u201378. https:\/\/doi.org\/10.1016\/j.neuroimage.2017.07.050.","journal-title":"NeuroImage"},{"issue":"11","key":"909_CR21","doi-asserted-by":"publisher","first-page":"e73377","DOI":"10.1371\/journal.pone.0073377","volume":"8","author":"Y Su","year":"2013","unstructured":"Su Y, D\u2019Angelo GM, Vlassenko AG, et al. Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS One. 2013;8(11):e73377. https:\/\/doi.org\/10.1371\/journal.pone.0073377.","journal-title":"PLoS One"},{"key":"909_CR22","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.neuroimage.2017.05.058","volume":"157","author":"A Maass","year":"2017","unstructured":"Maass A, Landau S, Baker SL, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer\u2019s disease. NeuroImage. 2017;157:448\u201363. https:\/\/doi.org\/10.1016\/j.neuroimage.2017.05.058.","journal-title":"NeuroImage"},{"issue":"17","key":"909_CR23","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647\u201359. https:\/\/doi.org\/10.1212\/WNL.0000000000008081.","journal-title":"Neurology"},{"issue":"3","key":"909_CR24","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A\u03b242 in humans. Ann Neurol. 2006;59(3):512\u201319. https:\/\/doi.org\/10.1002\/ana.20730.","journal-title":"Ann Neurol"},{"issue":"6","key":"909_CR25","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","volume":"28","author":"JT Leek","year":"2012","unstructured":"Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012;28(6):882\u201383. https:\/\/doi.org\/10.1093\/bioinformatics\/bts034.","journal-title":"Bioinformatics"},{"key":"909_CR26","doi-asserted-by":"publisher","DOI":"10.1201\/9781003277965","volume-title":"Model-based clustering, classification, and density estimation using mclust in R","author":"L Scrucca","year":"2023","unstructured":"Scrucca L, Fraley C, Murphy TB, Raftery AE. Model-based clustering, classification, and density estimation using mclust in R. Chapman and Hall\/CRC; 2023. https:\/\/doi.org\/10.1201\/9781003277965."},{"issue":"458","key":"909_CR27","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1198\/016214502760047131","volume":"97","author":"C Fraley","year":"2002","unstructured":"Fraley C, Raftery AE. Model-based clustering, discriminant analysis, and density estimation. J Am Stat Assoc. 2002;97(458):611\u201331. https:\/\/doi.org\/10.1198\/016214502760047131.","journal-title":"J Am Stat Assoc"},{"key":"909_CR28","doi-asserted-by":"publisher","first-page":"106373","DOI":"10.1016\/j.nbd.2023.106373","volume":"190","author":"J Timsina","year":"2024","unstructured":"Timsina J, Ali M, Do A, et al. Harmonization of CSF and imaging biomarkers in Alzheimer\u2019s disease: need and practical applications for genetics studies and preclinical classification. Neurobiol Dis. 2024;190:106373. https:\/\/doi.org\/10.1016\/j.nbd.2023.106373.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"909_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic accuracy of a plasma phosphorylated Tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 2024;81(3):255\u201363. https:\/\/doi.org\/10.1001\/jamaneurol.2023.5319.","journal-title":"JAMA Neurol"},{"issue":"9","key":"909_CR30","doi-asserted-by":"publisher","first-page":"6506","DOI":"10.1002\/alz.14140","volume":"20","author":"DJ Figdore","year":"2024","unstructured":"Figdore DJ, Griswold M, Bornhorst JA, et al. Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p-tau217 immunoassays. Alzheimers Dement. 2024;20(9):6506\u201316. https:\/\/doi.org\/10.1002\/alz.14140.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"909_CR31","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4103\/0974-7788.76794","volume":"1","author":"MK Goel","year":"2010","unstructured":"Goel MK, Khanna P, Kishore J. Understanding survival analysis: kaplan-meier estimate. Int J Ayurveda Res. 2010;1(4):274\u201378. https:\/\/doi.org\/10.4103\/0974-7788.76794.","journal-title":"Int J Ayurveda Res"},{"issue":"10","key":"909_CR32","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/sim.9681","volume":"42","author":"R Denz","year":"2023","unstructured":"Denz R, Klaa\u00dfen-Mielke R, Timmesfeld N. A comparison of different methods to adjust survival curves for confounders. Stat Med. 2023;42(10):1461\u201379. https:\/\/doi.org\/10.1002\/sim.9681.","journal-title":"Stat Med"},{"issue":"1","key":"909_CR33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3233\/JAD-220399","volume":"89","author":"J Timsina","year":"2022","unstructured":"Timsina J, Gomez-Fonseca D, Wang L, et al. Comparative analysis of Alzheimer\u2019s disease cerebrospinal fluid biomarkers measurement by multiplex SOMAscan platform and immunoassay-based approach. J Alzheimer\u2019s Dis. 2022;89(1):193\u2013207. https:\/\/doi.org\/10.3233\/JAD-220399.","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"6","key":"909_CR34","doi-asserted-by":"publisher","first-page":"100722","DOI":"10.1016\/j.xinn.2024.100722","volume":"5","author":"G Yu","year":"2024","unstructured":"Yu G. Thirteen years of clusterProfiler. The Innov. 2024;5(6):100722. https:\/\/doi.org\/10.1016\/j.xinn.2024.100722.","journal-title":"The Innov"},{"issue":"3","key":"909_CR35","doi-asserted-by":"publisher","first-page":"100141","DOI":"10.1016\/j.xinn.2021.100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. The Innov. 2021;2(3):100141. https:\/\/doi.org\/10.1016\/j.xinn.2021.100141.","journal-title":"The Innov"},{"issue":"6","key":"909_CR36","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s43587-025-00872-8","volume":"5","author":"G Heo","year":"2025","unstructured":"Heo G, Xu Y, Wang E, et al. Large-scale plasma proteomic profiling unveils diagnostic biomarkers and pathways for Alzheimer\u2019s disease. Nat Aging. 2025;5(6):1114\u201331. https:\/\/doi.org\/10.1038\/s43587-025-00872-8.","journal-title":"Nat Aging"},{"issue":"22","key":"909_CR37","doi-asserted-by":"publisher","first-page":"6309","DOI":"10.1016\/j.cell.2024.08.049","volume":"187","author":"Y Shen","year":"2024","unstructured":"Shen Y, Timsina J, Heo G, et al. CSF proteomics identifies early changes in autosomal dominant Alzheimer\u2019s disease. Cell. 2024;187(22):6309\u201326.e15. https:\/\/doi.org\/10.1016\/j.cell.2024.08.049.","journal-title":"Cell"},{"key":"909_CR38","doi-asserted-by":"publisher","unstructured":"Ali M, Timsina J, Western D, et al. Multi-cohort cerebrospinal fluid proteomics identifies robust molecular signatures across the Alzheimer disease continuum. Neuron. https:\/\/doi.org\/10.1016\/j.neuron.2025.02.014. Published online March 14, 2025","DOI":"10.1016\/j.neuron.2025.02.014"},{"key":"909_CR39","doi-asserted-by":"publisher","unstructured":"Wang Z, Chen Y, Gong K, et al. Cerebrospinal fluid proteomics identification of biomarkers for amyloid and tau PET stages. Cell Rep Med. 2025;6(4). https:\/\/doi.org\/10.1016\/j.xcrm.2025.102031.","DOI":"10.1016\/j.xcrm.2025.102031"},{"issue":"5","key":"909_CR40","doi-asserted-by":"publisher","first-page":"e0267298","DOI":"10.1371\/journal.pone.0267298","volume":"17","author":"M Ali","year":"2022","unstructured":"Ali M, Sung YJ, Wang F, et al. Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of klotho heterozygosity on disease risk. PLoS One. 2022;17(5):e0267298. https:\/\/doi.org\/10.1371\/journal.pone.0267298.","journal-title":"PLoS One"},{"issue":"1","key":"909_CR41","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40478-023-01563-4","volume":"11","author":"M Ali","year":"2023","unstructured":"Ali M, Archer DB, Gorijala P, et al. Large multi-ethnic genetic analyses of amyloid imaging identify new genes for Alzheimer disease. Acta Neuropathol Commun. 2023;11(1):68. https:\/\/doi.org\/10.1186\/s40478-023-01563-4.","journal-title":"Acta Neuropathol Commun"},{"issue":"5","key":"909_CR42","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00401-017-1685-y","volume":"133","author":"Y Deming","year":"2017","unstructured":"Deming Y, Li Z, Kapoor M, et al. Genome-wide association study identifies four novel loci associated with Alzheimer\u2019s endophenotypes and disease modifiers. Acta Neuropathol (berl). 2017;133(5):839\u201356. https:\/\/doi.org\/10.1007\/s00401-017-1685-y.","journal-title":"Acta Neuropathol (berl)"},{"key":"909_CR43","unstructured":"Plasma p-tau217 concordance with amyloid PET among ethnically diverse older adults - asken - 2024 - Alzheimer\u2019s & dementia: diagnosis, assessment & disease monitoring -. Wiley Online Library. Accessed December 6, 2024. https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/dad2.12617"},{"issue":"1","key":"909_CR44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.rvsc.2008.05.010","volume":"86","author":"M Mohri","year":"2009","unstructured":"Mohri M, Rezapoor H. Effects of heparin, citrate, and EDTA on plasma biochemistry of sheep: comparison with serum. Res Vet Sci. 2009;86(1):111\u201314. https:\/\/doi.org\/10.1016\/j.rvsc.2008.05.010.","journal-title":"Res Vet Sci"},{"issue":"5","key":"909_CR45","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.neuron.2019.01.056","volume":"101","author":"ME Belloy","year":"2019","unstructured":"Belloy ME, Napolioni V, Greicius MD. A quarter century of APOE and Alzheimer\u2019s disease: progress to date and the path forward. Neuron. 2019;101(5):820\u201338. https:\/\/doi.org\/10.1016\/j.neuron.2019.01.056.","journal-title":"Neuron"},{"issue":"1","key":"909_CR46","doi-asserted-by":"publisher","first-page":"e70042","DOI":"10.1002\/dad2.70042","volume":"17","author":"YL Chiu","year":"2025","unstructured":"Chiu YL, Yan SH, Fan YT, et al. A\u03b2-reactive T cell polyfunctionality response as a new biomarker for mild cognitive impairment. Alzheimers Dement Diagn Assess Dis Monit. 2025;17(1):e70042. https:\/\/doi.org\/10.1002\/dad2.70042.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"issue":"10","key":"909_CR47","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.3390\/cells9102190","volume":"9","author":"CA Musi","year":"2020","unstructured":"Musi CA, Agr\u00f2 G, Santarella F, Iervasi E, Borsello T. JNK3 as therapeutic target and biomarker in neurodegenerative and neurodevelopmental brain diseases. Cells. 2020;9(10):2190. https:\/\/doi.org\/10.3390\/cells9102190.","journal-title":"Cells"},{"issue":"11","key":"909_CR48","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/clinchem\/hvad139","volume":"69","author":"JH Kang","year":"2023","unstructured":"Kang JH, Korecka M, Lee EB, et al. Alzheimer disease biomarkers: moving from CSF to plasma for reliable detection of amyloid and tau pathology. Clin Chem. 2023;69(11):1247\u201359. https:\/\/doi.org\/10.1093\/clinchem\/hvad139.","journal-title":"Clin Chem"},{"issue":"12","key":"909_CR49","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.1002\/alz.13455","volume":"19","author":"K Blennow","year":"2023","unstructured":"Blennow K, Galasko D, Perneczky R, et al. The potential clinical value of plasma biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 2023;19(12):5805\u201316. https:\/\/doi.org\/10.1002\/alz.13455.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"909_CR50","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","volume":"30","author":"NR Barth\u00e9lemy","year":"2024","unstructured":"Barth\u00e9lemy NR, Salvad\u00f3 G, Schindler SE, et al. Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med. 2024;30(4):1085\u201395. https:\/\/doi.org\/10.1038\/s41591-024-02869-z.","journal-title":"Nat Med"},{"issue":"2","key":"909_CR51","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/alz.13485","volume":"20","author":"KE Foley","year":"2024","unstructured":"Foley KE, Winder Z, Sudduth TL, et al. Alzheimer\u2019s disease and inflammatory biomarkers positively correlate in plasma in the UK-ADRC cohort. Alzheimers Dement. 2024;20(2):1374\u201386. https:\/\/doi.org\/10.1002\/alz.13485.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"909_CR52","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1002\/alz.13664","volume":"20","author":"AM Suchy-Dicey","year":"2024","unstructured":"Suchy-Dicey AM, Longstreth WT Jr, Rhoads K, et al. Plasma biomarkers of Alzheimer\u2019s disease and related dementias in American Indians: the strong heart study. Alzheimers Dement. 2024;20(3):2072\u201379. https:\/\/doi.org\/10.1002\/alz.13664.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"909_CR53","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13195-024-01399-7","volume":"16","author":"PN Tariot","year":"2024","unstructured":"Tariot PN, Boada M, Lanct\u00f4t KL, et al. Relationships of change in clinical dementia rating (CDR) on patient outcomes and probability of progression: observational analysis. Alzheimers Res Ther. 2024;16(1):36. https:\/\/doi.org\/10.1186\/s13195-024-01399-7.","journal-title":"Alzheimers Res Ther"},{"issue":"20","key":"909_CR54","doi-asserted-by":"publisher","first-page":"10649","DOI":"10.1093\/cercor\/bhad312","volume":"33","author":"J Ding","year":"2023","unstructured":"Ding J, Shen C, Wang Z, et al. Tau-PET abnormality as a biomarker for Alzheimer\u2019s disease staging and early detection: a topological perspective. Cereb Cortex. 2023;33(20):10649\u201359. https:\/\/doi.org\/10.1093\/cercor\/bhad312.","journal-title":"Cereb Cortex"},{"issue":"2","key":"909_CR55","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","volume":"15","author":"R La Joie","year":"2019","unstructured":"La Joie R, Ayakta N, Seeley WW, et al. Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology. Alzheimers Dement. 2019;15(2):205\u201316. https:\/\/doi.org\/10.1016\/j.jalz.2018.09.001.","journal-title":"Alzheimers Dement"},{"issue":"15","key":"909_CR56","doi-asserted-by":"publisher","first-page":"e1580","DOI":"10.1212\/WNL.0000000000009240","volume":"94","author":"JD Doecke","year":"2020","unstructured":"Doecke JD, P\u00e9rez-Grijalba V, Fandos N, et al. Total A\u03b242\/A\u03b240 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis. Neurology. 2020;94(15):e1580\u201391. https:\/\/doi.org\/10.1212\/WNL.0000000000009240.","journal-title":"Neurology"},{"issue":"9","key":"909_CR57","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-022-01925-w","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0 M, Ashton NJ, Shekari M, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2022;28(9):1797\u2013801. https:\/\/doi.org\/10.1038\/s41591-022-01925-w.","journal-title":"Nat Med"},{"issue":"1","key":"909_CR58","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13195-024-01555-z","volume":"16","author":"AH Dyer","year":"2024","unstructured":"Dyer AH, Dolphin H, O\u2019Connor A, et al. Performance of plasma p-tau217 for the detection of amyloid-\u03b2 positivity in a memory clinic cohort using an electrochemiluminescence immunoassay. Alzheimers Res Ther. 2024;16(1):186. https:\/\/doi.org\/10.1186\/s13195-024-01555-z.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"909_CR59","doi-asserted-by":"publisher","first-page":"e70003","DOI":"10.1002\/dad2.70003","volume":"16","author":"RZ Rousset","year":"2024","unstructured":"Rousset RZ, Claessen T, van Harten AC, et al. Performance of plasma p-tau217 and NfL in an unselected memory clinic setting. Alzheimers Dement Diagn Assess Dis Monit. 2024;16(4):e70003. https:\/\/doi.org\/10.1002\/dad2.70003.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"909_CR60","doi-asserted-by":"publisher","first-page":"e97.1","DOI":"10.1016\/j.neurobiolaging.2020.03.013","volume":"93","author":"B Lim","year":"2020","unstructured":"Lim B, Sando SB, Gr\u00f8ntvedt GR, Br\u00e5then G, Diamandis EP. Cerebrospinal fluid neuronal pentraxin receptor as a biomarker of long-term progression of Alzheimer\u2019s disease: a 24-month follow-up study. Neurobiol Of Aging. 2020;93:.e97.1\u201377. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2020.03.013.","journal-title":"Neurobiol Of Aging"},{"issue":"1","key":"909_CR61","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13195-022-01113-5","volume":"14","author":"EB Dammer","year":"2022","unstructured":"Dammer EB, Ping L, Duong DM, et al. Multi-platform proteomic analysis of Alzheimer\u2019s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome. Alzheimers Res Ther. 2022;14(1):174. https:\/\/doi.org\/10.1186\/s13195-022-01113-5.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"909_CR62","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3233\/JAD-2008-14106","volume":"14","author":"M Menendez-Gonzalez","year":"2008","unstructured":"Menendez-Gonzalez M, Castro-Santos P, Suarez A, et al. Value of measuring plasmatic levels of Neurosin in the diagnosis of Alzheimer\u2019s disease. J Alzheimer\u2019s Dis. 2008;14(1):59\u201367. https:\/\/doi.org\/10.3233\/JAD-2008-14106.","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"1","key":"909_CR63","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13195-018-0336-4","volume":"10","author":"K Patra","year":"2018","unstructured":"Patra K, Soosaipillai A, Sando SB, et al. Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer\u2019s disease. Alzheimers Res Ther. 2018;10(1):9. https:\/\/doi.org\/10.1186\/s13195-018-0336-4.","journal-title":"Alzheimers Res Ther"},{"key":"909_CR64","unstructured":"Differences in neuropathologic characteristics across the lewy body dementia spectrum | neurology. https:\/\/www.neurology.org\/doi\/10.1212\/01.wnl.0000249130.63615.cc. Accessed March 7, 2025"},{"issue":"1","key":"909_CR65","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jagp.2013.03.001","volume":"23","author":"P Donaghy","year":"2015","unstructured":"Donaghy P, Thomas AJ, O\u2019Brien JT. Amyloid PET imaging in Lewy Body Disorders. Am J Geriatr Psychiatry. 2015;23(1):23\u201337. https:\/\/doi.org\/10.1016\/j.jagp.2013.03.001.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"909_CR66","doi-asserted-by":"publisher","first-page":"fcad057","DOI":"10.1093\/braincomms\/fcad057","volume":"5","author":"EM Jonaitis","year":"2023","unstructured":"Jonaitis EM, Janelidze S, Cody KA, et al. Plasma phosphorylated tau 217 in preclinical Alzheimer\u2019s disease. Brain Commun. 2023;5(2):fcad057. https:\/\/doi.org\/10.1093\/braincomms\/fcad057.","journal-title":"Brain Commun"},{"issue":"8","key":"909_CR67","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772\u201381. https:\/\/doi.org\/10.1001\/jama.2020.12134.","journal-title":"JAMA"},{"issue":"9","key":"909_CR68","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.parkreldis.2014.06.004","volume":"20","author":"J Siuda","year":"2014","unstructured":"Siuda J, Fujioka S, Wszolek ZK. Parkinsonian syndrome in familial frontotemporal dementia. Parkinsonism Relat Disord. 2014;20(9):957\u201364. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.06.004.","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"909_CR69","doi-asserted-by":"publisher","first-page":"e209418","DOI":"10.1212\/WNL.0000000000209418","volume":"102","author":"K Bolsewig","year":"2024","unstructured":"Bolsewig K, van Unnik AAJM, Blujdea ER, et al. Association of plasma amyloid, P-Tau, GFAP, and NfL with CSF, clinical, and cognitive features in patients with dementia with Lewy Bodies. Neurology. 2024;102(12):e209418. https:\/\/doi.org\/10.1212\/WNL.0000000000209418.","journal-title":"Neurology"},{"issue":"3","key":"909_CR70","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1093\/brain\/awh725","volume":"129","author":"P Tiraboschi","year":"2006","unstructured":"Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J. What best differentiates Lewy body from Alzheimer\u2019s disease in early-stage dementia? Brain. 2006;129(3):729\u201335. https:\/\/doi.org\/10.1093\/brain\/awh725.","journal-title":"Brain"},{"key":"909_CR71","doi-asserted-by":"crossref","unstructured":"Pathogenesis of DJ-1\/PARK7-mediated Parkinson\u2019s disease. https:\/\/www.mdpi.com\/2073-4409\/13\/4\/296. Accessed January 22, 2025","DOI":"10.3390\/cells13040296"},{"key":"909_CR72","doi-asserted-by":"publisher","unstructured":"Ali M, Erabadda B, Chen Y, et al. Shared and disease-specific pathways in frontotemporal dementia and Alzheimer\u2019s and Parkinson\u2019s diseases. Nat Med. Published online July 15, 2025:1\u201311. https:\/\/doi.org\/10.1038\/s41591-025-03833-1.","DOI":"10.1038\/s41591-025-03833-1"},{"key":"909_CR73","doi-asserted-by":"publisher","unstructured":"Xu Y, Western D, Heo G, et al. Protein-based diagnosis and analysis of Co-pathologies across neurodegenerative diseases: large-scale AI-Boosted CSF and Plasma classification. medrxiv Prepr Serv Health Sci. Published online July 10, 2025: 2025.07.09.25331192. https:\/\/doi.org\/10.1101\/2025.07.09.25331192.","DOI":"10.1101\/2025.07.09.25331192"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00909-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-025-00909-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00909-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T17:54:52Z","timestamp":1763402092000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-025-00909-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["909"],"URL":"https:\/\/doi.org\/10.1186\/s13024-025-00909-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6440485\/v1","asserted-by":"object"}]},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"13 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"CC is a member of the scientific advisory board of Circular Genomics and owns stocks and is on the scientific advisory board of ADmit and Alamar. CC consults for Sanofi, NovoNordisk, and Owkin. CC has received research support from GSK, Danaher and EISAI. GF receives consulting fees from Alamar Biosciences. D.M.H. co-founded, has equity, receives royalty income, and is on the scientific advisory board of C2N Diagnostics. He is on the scientific advisory boards of Denali, Genentech, Cajal Neuroscience, and Switch Therapeutics and consults for Roche and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}